Skip to main content
. Author manuscript; available in PMC: 2011 Feb 2.
Published in final edited form as: J Cell Physiol. 2008 Jul;216(1):29–37. doi: 10.1002/jcp.21426

Figure 6. Retinal thickness after topical delivery of TG100801 in a rat model of retinal vein occlusion.

Figure 6

A retinal vein occlusion study was performed as described in Fig. 5, except that only one dose of TG100801 (1%) was investigated, and at study end retinal thickness was measured by optical coherence tomography (OCT; A–C). Representative OCT scans taken from naïve (A), thrombosed, vehicle-treated (B), or thrombosed, 1% TG100801-treated (C) animals. (D) Retinal area (µm2) determined from six 5 mm OCT scans (means ± SEM, n= 17–21; * TG100801 group differs from vehicle group with P< 0.05).